Cardiff Lexington Corp

Proposed Combination Would Significantly Expand Cardiff Lexington's Musculoskeletal and Ancillary Healthcare OperationsLEXINGTON, KY / ACCESS Newswire / September 24, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a healthcare holding company focused on orthopedics, spine care, pain management and related healthcare services, today announced that it has entered into a letter of intent ("LOI") with the owners of a multi-location musculoskeletal healthcare platform regarding a proposed business combination (the "Proposed Transaction").The acquisition target (the "Target") operates an established comprehensive multi-location musculoskeletal healthcare platform serving patients in multiple states. The Company believes that the Proposed Transaction would substantially increase the scale of Cardiff Lexington's healthcare operations and further the Company's strategy of developing an integrated regional healthcare platform encompassing orthopedic and spine care, diagnostic imaging, physical therapy and other complementary related healthcare services.Strategic BenefitsCardiff Lexington believes the Proposed Transaction could create a significantly larger integrated musculoskeletal healthcare platform with opportunities to increase utilization of existing clinical infrastructure, expand ancillary services and pursue additional growth opportunities.The LOI provides Cardiff Lexington with a 30-month option following closing to acquire, at appraised fair market value, certain healthcare facilities utilized by the Target, together with rights of first refusal thereafter. These rights extend to certain facilities currently under development."We believe this proposed combination has the potential to create a cornerstone regional healthcare platform for Cardiff Lexington as it is complimentary with and synergistic to our existing Nova organization, and moreover, will be a force multiplier in accelerating our strategic long term growth and expansion," said its Chairman and CEO, Alex Cunningham. "The combination of an established physician-led clinical organization, complementary ancillary services and the opportunity for future ambulatory surgery center integration is closely aligned with our Nova Ortho and Spine operations and the healthcare strategy we are building."Proposed Transaction StructureThe Company would pay to the sellers an aggregate purchase price consideration of up to $104 million (the "Purchase Price"). Under the LOI, Cardiff Lexington would acquire the equity interests of the Target for consideration consisting principally of:$30 million in cash at closing (before debt retirement, transaction costs, and escrow);$10 million unsecured notes payable two years following closing;Preferred equity based on the value attributed to the preferred equity under the LOI, resulting in the sellers collectively owning 35% of Cardiff Lexington's fully diluted equity post-closing; andUp to $12 million of additional Cardiff Lexington common stock tied to the Target achieving specified EBITDA performance thresholds for 2027, 2028, and 2029.The preferred equity would carry a non-participating 1x preference senior to Cardiff Lexington common stock, subject to potential seniority of securities issued to cash investors. The preferred equity may convert into Cardiff Lexington common stock upon a qualifying listing on a national securities exchange at a valuation greater than $120 million.The transaction structure is intended to provide the sellers with significant continuing ownership in Cardiff Lexington and align the interests of the Target's existing leadership with Cardiff Lexington and its shareholders following

LEXINGTON, KY / ACCESS Newswire / August 12, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that it has filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026 with the U.S. Securities and Exchange Commission. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "During the first half of 2026, we continued to execute on our long-term strategy to establish Nova Ortho and Spine as a leading healthcare network and provide best-in-class care to a severely underserved patient population. During the second quarter, we opened our 12th Nova Ortho and Spine location in Tallahassee, Florida, representing a strategic metropolitan location with high patient volume and visibility, and we continue to strengthen our team with the addition of leading doctors, nurses, and operators. We remain confident that we're fulfilling a critical healthcare need in a highly attractive geographic market, and we see this as a strong opportunity for continued growth. "While execution has been strong, the first half of the year has not been without its challenges. Year-to-date revenue was down compared to last year, and though we saw an increase in both new patients and billed surgical procedures in the year to date period, we recognized a lower implicit realization rate on patient case claim settlements during the first half of the year. Despite this, gross profit in the first half was strong at 57%, and we realized a slight adjusted non-GAAP EBITDA loss of $14,000 compared with non-GAAP adjusted EBITDA of $1.3 million in the first half of 2025. "We're seeing significant demand for our services, however, working capital constraints have limited our ability to capitalize on opportunities and has required us to access capital at high costs. We continue to evaluate opportunities for debt restructuring and equity infusions to offset this current cost of capital. That said, we have strong brand recognition in the markets we serve, and we remain committed to driving execution and continuing to provide the best available care to our patients across our network of Nova Ortho and Spine locations throughout Florida and Georgia, where there is strong demand. "Looking ahead, our focus is on returning our business to historical levels of performance while driving long-term, sustained value for our shareholders. Over the course of several years, we have proven that this model can deliver consistent revenue growth and high returns on invested capital, and we remain confident in our ability to build on that as we enhance our access to working capital and pursue the many opportunities available to us in this exciting market. We're encouraged by what's ahead, and we thank you for your continued support and belief in Cardiff Lexington," Mr. Cunningham concluded. Financial tables are below, and the Company's Quarterly Report on Form 10-Q is available on the SEC's website at www.sec.gov and on the Investor Relations section of the Company's website. Conference Call Cardiff Lexington will hold a conference call and webcast for investors today, August 12, 2026, at 11:00 a.m. Eastern Time. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 876877. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/54266 An online archive of the webcast will be available at the above webcast li

LEXINGTON, KY / ACCESS Newswire / August 6, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that the Company will host an investor conference call to discuss its financial and operating results for the second quarter ended June 30, 2026, on Wednesday, August 12, 2026, at 11:00 am ET. The Company will release its financial and operating results for the second quarter ended June 30, 2026, prior to the call on Wednesday, August 12, 2026. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 876877. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/54266 An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Wednesday, August 26, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 54266 to access the replay. About Cardiff Lexington Corporation: Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care. The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets. FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Cardiff Lexington Investor Relationsinvestorrelations@cardifflexington.com(800) 628-2100 ext. 705 or IMS Investor Relationscardifflexington@imsinvestorrelations.com(203) 972-9200 SOURCE: Cardiff Lexington Corporation View the original press release on ACCESS Newswire

- Adds high visibility metropolitan location with potential for high patient volume - - 12th surgical center as company executes strategy to expand network throughout southeast and mid-Atlantic region - LEXINGTON, KY / ACCESS Newswire / June 29, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that its Nova Ortho and Spine subsidiary has added Southeastern Surgery Center in Tallahassee, Florida to its growing network of surgical facilities, enhancing access to advanced orthopedic and spine care for patients in this region.Southeastern Surgery Center has earned a strong reputation over many years of operation, recognized for its commitment to exceptional patient care, outstanding patient satisfaction, and stringent patient safety standards. Nova Ortho and Spine has begun performing minimally invasive pain management and spine procedures at Southeastern Surgery Center. These advanced procedures offer patients shorter recovery times, and less postoperative discomfort. The practice plans to expand its surgical offerings at the facility to include open procedures in the near future.Dr. Kevin Fitzgerald, Managing Partner of Nova Ortho and Spine, commented, "We are very pleased to be able to provide these critically needed pain procedures right here in Tallahassee. Not only are we making treatment more convenient for our local community, but we're also helping patients achieve pain relief in a shorter timeframe. The staff at Southeastern Surgery Center is extraordinary, and their wealth of knowledge, dedication to patient care, and constant professionalism ensure that our patients receive the best care available."Alex Cunningham, Chief Executive Officer of Cardiff Lexington Corporation, commented, "The addition of Southeastern Surgery Center as the 12th surgical center in the Nova Ortho and Spine network aligns perfectly with our long-term strategy to provide best in class patient-centered care to underserved populations. As the capital city of Florida, Tallahassee represents a strategic metropolitan location with high patient volume and visibility. This is a natural next step in our continued expansion in the southeast US and mid-Atlantic."Southeastern Surgery Center is located at 2000 Centre Point Boulevard, Tallahassee, Florida 32308.About Nova Ortho and SpineNova Ortho and Spine is a growing provider of orthopedic, spine, and musculoskeletal healthcare services focused on delivering patient-centered treatment solutions through experienced providers, advanced clinical care, and compassionate service. With multiple locations throughout Florida, Nova Ortho and Spine continues to expand access to high-quality orthopedic and spine care for the communities it serves across South Florida and the Treasure Coast region.About Cardiff Lexington CorporationCardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care.The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets.FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the mean

LEXINGTON, KY / ACCESS Newswire / May 20, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that Nova Ortho and Spine, a wholly owned subsidiary of Cardiff Lexington Corporation, has opened a new location in Stuart, Florida. This new location further strengthens Nova Ortho and Spine's expanding regional network of healthcare facilities throughout Florida and supports the organization's broader strategy of increasing accessibility to specialized orthopedic and spine services in underserved and high-growth markets. Strategically positioned along the Federal Highway corridor with convenient access to major regional transportation routes, the newly developed 2,975-square-foot clinic expands Nova Ortho and Spine's footprint along Florida's Treasure Coast and will provide comprehensive orthopedic, spine, and musculoskeletal care services to patients throughout Stuart, Palm City, Jensen Beach, Port St. Lucie, and surrounding Martin and St. Lucie County communities. The facility is designed to provide efficient patient flow, modern clinical infrastructure, and a patient-centered care environment focused on orthopedic evaluation, spine care, diagnostics, and non-surgical treatment options. Martin County and neighboring St. Lucie County continue to experience significant population growth, driven by both residential expansion and an increasing retiree population seeking high-quality healthcare services in South Florida. According to recent regional demographic estimates, the combined population of Martin and St. Lucie Counties now exceeds 650,000 residents, with continued growth projected over the coming decade. The Treasure Coast region also maintains one of Florida's highest concentrations of residents aged 55 and older - a demographic frequently requiring orthopedic, spine, pain management, and mobility-related healthcare services. "We are excited to serve this growing community and proud of our exceptional clinical staff and highly experienced providers," said Dr. Kevin Fitzgerald. "The Treasure Coast continues to experience substantial population growth, and this new location allows us to expand access to high-quality orthopedic and spine care while remaining focused on delivering outstanding patient outcomes and compassionate service." Alex H. Cunningham, Chief Executive Officer of Cardiff Lexington Corporation, added, "The opening of our Stuart location represents another important milestone in Nova Ortho and Spine's strategic growth throughout Florida. We believe the Treasure Coast region presents a strong long-term opportunity due to its continued population expansion, favorable demographics, and increasing demand for specialized musculoskeletal healthcare services. This location prioritizes patient demographics as Nova remains committed to investing in high-quality facilities, experienced providers, and scalable healthcare infrastructure designed to better serve patients and communities across the region." The facility will provide convenient access for patients seeking evaluation and treatment for conditions involving: Orthopedic injuries and disorders Neck and back pain Spine-related conditions Musculoskeletal injuries Joint pain and mobility issues Personal injury-related orthopedic care Non-surgical pain management solutions Nova Ortho and Spine's continued expansion throughout South Florida reflects increasing patient demand for specialized musculoskeletal care and the organ

LEXINGTON, KY / ACCESS Newswire / May 19, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) today announced financial results for the first quarter ended March 31, 2026. Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "We continue to strengthen and expand our network of Nova Ortho and Spine locations to support growing patient demand with a focus on more high value procedures, and we remain confident in our ability to build a scalable platform through organic growth and acquisitions that deliver exceptional outcomes for patients. Furthermore, our recent upgrade to the OTCQX market represents an important step in increasing our visibility and credibility among institutional investors as we execute our strategic initiatives to enhance our access to working capital and drive sustainable, long-term growth and shareholder value." First Quarter 2026 Financial Results Total revenue was $2.2 million compared with $2.9 million in the first quarter of 2025. The decrease in revenue is mainly attributable to a decrease in surgical procedures in the first quarter of 2026 compared to the first quarter of 2025. Gross profit was $1.3 million, or 59.3% of total revenue, compared with $1.8 million, or 63.1% of total revenue in the first quarter of 2025. Total operating expenses increased to $1.8 million compared with $1.3 million in the first quarter of 2025, primarily related to share based compensation of $664,000 in the first quarter of 2026, compared with no share based compensation in the first quarter of 2025. SG&A expense was $1.2 million, or 52.4% of revenue in the first quarter of 2026, compared with $1.3 million, or 43.9% of revenue in the first quarter of 2025. Loss from continuing operations was $511,000, or (23.0%) of total revenue, in the first quarter of 2026, compared with income from continuing operations of $544,000, or 18.7% of total revenue, in the first quarter of 2025. Net loss in the first quarter of 2026 was $3.1 million compared with net loss of $451,000 in the first quarter of 2025. Included in net loss for the three months ended March 31, 2026, was interest expense of $1.9 million compared with interest expense of $1.0 million in the first quarter of 2025. The increase in interest expense is primarily attributable to the increase in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit. Non-GAAP adjusted EBITDA, which excludes interest expense, was $164,000 compared with non-GAAP adjusted EBITDA of $546,000 in the first quarter of 2025. Balance Sheet Cash totaled $684,000 as of March 31, 2026. Total assets increased 4.1% to $30.3 million as of March 31, 2026. Conference Call Cardiff Lexington will hold a conference call and webcast for investors today, May 19, 2026, at 11:00 a.m. Eastern Time. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 204811. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/53976 An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Tuesday, June 2, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53976 to access the replay. ----- About Cardiff Lexington Corporation: Cardiff Lexington Corporation is a publ

LEXINGTON, KY / ACCESS Newswire / May 14, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that the Company will host an investor conference call to discuss its financial and operating results for the first quarter ended March 31, 2026, on Tuesday, May 19, 2026, at 11:00 am ET. The Company will release its financial and operating results for the first quarter ended March 31, 2026, prior to the call on Tuesday, May 19, 2026. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 204811. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/53976 An online archive of the webcast will be available at the above webcast link. A replay of the conference call will be available one hour after completion of the call until Tuesday, June 2, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53976 to access the replay. About Cardiff Lexington Corporation: Cardiff Lexington Corporation is a publicly traded healthcare services holding company focused on building a regional and national platform in orthopedic, spine, and pain management markets. Through its operating subsidiaries, including Nova Ortho and Spine, the Company delivers a comprehensive suite of services including diagnostics, interventional pain management, surgical coordination, and specialty care. The Company's strategy is centered on disciplined capital deployment, operational efficiency, and scalable growth through acquisitions and strategic partnerships within highly fragmented healthcare markets. FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Cardiff Lexington Investor Relationsinvestorrelations@cardifflexington.com(800) 628-2100 ext. 705 or IMS Investor Relationscardifflexington@imsinvestorrelations.com(203) 972-9200 SOURCE: Cardiff Lexington Corporation View the original press release on ACCESS Newswire

LEXINGTON, KY / ACCESS Newswire / April 9, 2026 / Cardiff Lexington Corporation (OTCQX:CDIX) ("Cardiff Lexington" or the "Company"), a publicly traded healthcare services holding company focused on orthopedic, spine, and pain management platforms, today announced that its common stock has been approved to trade on the OTCQX® Best Market, the highest-level market of the OTC Markets, effective at the commencement of trading on Thursday, April 9th, 2026. The Company will continue to trade under the symbol "CDIX". The OTCQX Best Market is designed for established, investor-focused companies and requires high financial standards, strong corporate governance, and compliance with applicable securities laws. Strategic Positioning and Market Advancement Upgrading to OTCQX from the OTCQB® Venture Market reflects Cardiff Lexington's continued commitment to enhanced transparency and maintaining the highest governance and financial reporting standards available to companies trading on the OTC Markets. "We view our upgrade to the OTCQX Best Market as a meaningful milestone in Cardiff Lexington's evolution as a disciplined, growth-oriented healthcare platform," said Alex H. Cunningham, Chief Executive Officer of Cardiff Lexington Corporation. "This transition strengthens our visibility within the institutional investor community and reinforces our commitment to building a scalable, high-margin healthcare enterprise with a clear path toward a national exchange listing. Listing on a national exchange would significantly enhance access to working capital to support increased patient volume and procedural throughput without relying on higher-cost financing structures and accelerate our accounts receivable conversion cycles. We look forward to leveraging this enhanced OTCQX visibility alongside our high-margin operating model to drive sustainable revenue growth, expand margins, and enhance long-term shareholder value." Demonstrated Financial Performance and Operating Leverage Cardiff Lexington has demonstrated consistent financial growth and operating performance driven by its focused healthcare platform strategy. For the fiscal year ended December 31, 2025, the Company reported: Revenue of approximately $11.5 million compared with $8.3 million in full year 2024, representing a 39.5% increase Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024. Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024. Total assets increased 21.6% to $29.1 million as of December 31, 2025 This performance reflects a high-margin operating model within the orthopedic and spine care sector and underscores management's focus on scalable, capital-efficient growth. Execution of Proven Three-Pillar Growth Strategy Cardiff Lexington continues to execute on its differentiated three-pillar strategy, designed to drive sustainable revenue growth, expand margins, and enhance long-term shareholder value: Core Cash Flow Platform - Acquisition and optimization of physician orthopedic and related practices to generate consistent, recurring revenue streams Asset Acquisition -

39.5% increase in FY25 total revenue to $11.5 million compared to FY 2024 62.7% increase in FY25 gross profit to $7.2 million compared to FY 2024 $1.1 million in income from continuing operations in FY 2025 Strengthening operational team and capital structure to position Company for next phase of growth LEXINGTON, KY / ACCESS Newswire / March 16, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced financial results for the fourth quarter and full year ended December 31, 2025.Alex Cunningham, Chief Executive Officer of Cardiff Lexington, commented, "2025 was a year of strong strategic execution as we continued to enhance our Nova Ortho and Spine footprint and offerings while making meaningful progress on our long-term goals. Notably, full year revenue increased 39.5% on a GAAP basis in 2025 compared with 2024, supported by our operations in numerous diverse locations throughout Florida and Georgia where we are seeing strong demand for our services. Operationally, we've shifted our focus to more higher value surgical procedures, and our patient volumes continue to increase, with an average of between 270 and 375 patients treated per month across all our locations."During the fourth quarter, we strengthened the Nova Ortho and Spine team with the addition of leading healthcare talent and entered a strategic partnership with Doctors' Memorial Hospital in Perry, Florida to bring our leading services to patients in this area of the state. Subsequent to the close of the quarter, we improved our capital structure with the execution of a 1-for-3 reverse split as a part of our planned uplisting to a major US stock exchange. We believe this will strengthen our capital markets profile and enhance our visibility, liquidity, and access to capital to support our anticipated growth as we continue to bring our world-class care to an underserved patient population," Mr. Cunningham concluded.Full Year 2025 Financial HighlightsTotal revenue increased 39.5% to $11.5 million compared with $8.3 million in full year 2024, primarily related to higher patient volume and a shift to more higher value surgical procedures throughout the year. Revenue in full year 2024 included one-time adjustments of $2.8 million. Non-GAAP adjusted revenue, which excludes this one-time adjustment to revenue, was $11.1 million for full year 2024.Gross profit increased to $7.2 million, or 62.5% of total revenue, compared with $4.4 million, or 53.6% of total revenue in full year 2024.Total operating expenses increased to $6.1 million compared with $4.6 million in full year 2024, primarily related to increased SG&A expense of $5.3 million, or 46.2% of revenue, compared with $4.1 million, or 49.1% of revenue, for the full year 2024.Operating income increased to $1.1 million, or 9.5% of total revenue, compared with operating loss of $(193,000), or (2.3%) of total revenue, in full year 2024.Net loss in full year 2025 was $(5.5 million) compared with net loss of $(3.3 million) in full year 2024. Included in full year 2025 was interest expense of $(6.8 million) compared with interest expense of $(3.0 million) in full year 2024. This increase in interest expense is primarily related to increases in initial and incremental fees charged on the number of existing purchases and claims under the Company's line of credit.Non-GAAP adjusted EBITDA, which excludes interest expense, was $1.8 million compared with non-GAAP adjusted EBITD

LEXINGTON, KY / ACCESS Newswire / March 12, 2026 / Cardiff Lexington Corporation (OTCQB:CDIX) today announced that the Company will host an investor conference call to discuss its financial and operating results for the fourth quarter and full year ended December 31, 2025, on Monday, March 16, 2026, at 11:00 am ET. The Company will release its financial and operating results for the fourth quarter and full year ended December 31, 2025, prior to the call on Monday, March 16, 2026. Shareholders and interested parties may participate in the conference call by dialing (888) 506-0062 and international participants should dial (973) 528-0011 and use access code: 860308. The call and the accompanying slide deck will also be webcast at: https://www.webcaster5.com/Webcast/Page/3131/53650 The conference call and slide deck may also be accessed via the Investor Relations page of the Company's website at https://investor.cardifflexington.com/overview/default.aspx. Please allow extra time prior to the call to visit the site. An online archive of the webcast will be available on the Investor Relations page of the Company's website following the call at https://investor.cardifflexington.com/overview/default.aspx. A replay of the conference call will be available one hour after completion of the call until Monday, March 30, 2026, by dialing (877) 481-4010 and international participants should dial (919) 882-2331. All callers must use access code 53650 to access the replay. About Cardiff Lexington Corporation: Cardiff Lexington Corporation (OTCQB:CDIX) is a targeted healthcare holding company dedicated to acquiring and building middle-market niche health care clinics, primarily in Orthopedics, Spine Care, and Pain Management. The Company's partnership-driven culture emphasizes service excellence, teamwork, accountability, and performance. All current revenue is derived from Nova Ortho and Spine, LLC, which operates a network of regional specialty and ancillary orthopedic care centers across Florida and Georgia. These facilities provide traumatic injury patients with comprehensive diagnostic and surgical services, primary care evaluations, interventional pain management, and specialty consultations. For more information on Cardiff Lexington Corporation, you may access the company's website at https://cardifflexington.com/ FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's business, the Company's liquidity position, the Company's ability to obtain new business, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur. Cardiff Lexington Investor Relationsinvestorsrelations@cardifflexington.com(800) 628-2100 ext. 705 or IMS Investor Relationscardifflexington@imsinvestorrelations.com(203) 972-9200 SOURCE: Cardiff Lexington Corporation View